Jun 12, 2008 - InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL(TM)), announced today that it has received notices of allowance on several of its patent applications both in the United States Patent & Trademark Office (USPTO) and in the European Patent Office (EPO) covering its DXL(TM) technology. The patents following issuance will be titled "THERAPEUTIC APPLICATIONS OF NONCOVALENT DIMERIZING ANTIBODIES" in the U.S. and "METHOD OF AFFINITY CROSS-LINKING BIOLOGICALLY ACTIVE, IMMUNOGENIC PEPTIDES TO ANTIBODIES" in Europe, and relate to the Company's ability to develop and manufacture DXL(TM) antibodies. The new patents name InNexus scientists as inventors and are solely owned by InNexus.
The details can be read here.
No comments:
Post a Comment